Warning Letter — All Ketamine HCL / www.allketaminehcl.com
The FDA issued a warning letter to All Ketamine HCL for marketing and distributing unapproved drug products through its website. The Center for Drug Evaluation and Research identified regulatory violations related to the sale of ketamine hydrochloride on the company's digital platform.
This enforcement action affects the operators of www.allketaminehcl.com and entities involved in the digital marketing and online distribution of ketamine-based products. It also serves as a notice to regulatory and compliance departments within the pharmaceutical e-commerce sector.
This action indicates continued FDA scrutiny of online platforms bypasssing traditional prescription and approval pathways. For regulatory professionals, it highlights the risks associated with marketing controlled substances without required federal approvals, which may lead to significant enforcement actions or criminal investigations. The focus on ketamine suggests an emphasis on substances with high potential for misuse or those requiring specific safety controls.
Ensure all digital storefronts and marketing assets strictly align with approved labeling. Conduct immediate audits of online distribution channels to verify that products are not being marketed for unapproved indications or sold without required federal oversight.
FDA Warning Letter issued to: All Ketamine HCL / www.allketaminehcl.com. 06/23/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/all-ketamine-hcl-wwwallketaminehclcom-725150-06232026
Open in openFDA / FDA.gov